• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, September 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Science

UTHealth receives NIH grant to develop individualized therapies for cocaine addiction

Bioengineer by Bioengineer
November 8, 2016
in Science
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

HOUSTON – (Nov. 7, 2016) – Identifying more effective treatment strategies tailored to individual responses for patients overcoming addiction to cocaine is the focus of a new clinical trial at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth).

The study, funded with a $1.9 million grant from the National Institute on Drug Abuse (NIDA; R01DA039125), is led by Joy M. Schmitz, Ph.D., Louis A. Faillace Professor in the Department of Psychiatry and Behavioral Sciences and director of the Center for Neurobehavioral Research on Addiction (CNRA) at McGovern Medical School at UTHealth.

"What we have found is that no single treatment is appropriate for everyone," Schmitz said. "Addiction treatments need to be adjusted based on patient characteristics and response in order to be most effective."

Studies have shown that the most effective treatment to date for cocaine addiction is behavior therapy involving motivational incentives, which can result in initial abstinence rates of 40 percent. This approach uses small reward incentives such as gift cards to encourage positive behavior change, such as abstaining from drugs.

"Chronic cocaine use can throw off the balance of the brain reward system to the point where behavior is fully directed or motivated toward using the drug. Incentive-based therapy is used to help rebalance response to reward by offering natural or non-drug incentives that can compete with that of cocaine," Schmitz said.

The study aims to boost the effectiveness of motivational incentives in certain individuals by adding a therapy that teaches mindfulness skills.

"Acceptance and commitment therapy is a new evidence-based behavioral therapy that focuses on helping the individual handle difficult feelings and thoughts without using drugs to escape. Acceptance is about being willing to experience negative feelings, like strong sensations of craving, without letting the feeling take control or interfere with valued living," Schmitz said.

Researchers predict that for a certain subgroup of patients, the combination of motivational incentives and skills training to tolerate distress will improve patients' chances of achieving abstinence, Schmitz said. "For those who do not respond, however, a third phase of the trial will test whether adding a dopamine-enhancing medication, modafinil, is beneficial," she said.

The clinical trial, called Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention (ClinicalTrials.gov NCT02896712), will enroll 160 patients. NIDA is part of the National Institutes of Health (NIH).

Co-Investigators at UTHealth are Angela Stotts, Ph.D., professor and vice chair for research in the Department of Family & Community Medicine; Michael Weaver, M.D., professor and medical director at CNRA; Charles Green, Ph.D., associate professor in the Department of Pediatrics, Center for Clinical Research and Evidence-Based Medicine; and Anka Vujanovic, Ph.D., adjunct associate professor in the Department of Psychiatry and Behavioral Sciences.

For more information, please call 713-500-DRUG (3784).

###

Media Contact

Deborah Mann Lake
[email protected]

http://www.uthouston.edu

Share12Tweet7Share2ShareShareShare1

Related Posts

Five or more hours of smartphone usage per day may increase obesity

July 25, 2019
IMAGE

NASA’s terra satellite finds tropical storm 07W’s strength on the side

July 25, 2019

NASA finds one burst of energy in weakening Depression Dalila

July 25, 2019

Researcher’s innovative flood mapping helps water and emergency management officials

July 25, 2019
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    154 shares
    Share 62 Tweet 39
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    143 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    117 shares
    Share 47 Tweet 29
  • Do people and monkeys see colors the same way?

    112 shares
    Share 45 Tweet 28

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Novo Nordisk Foundation Introduces Innovative Funding Model

Dual Fermentation of Kudzu Boosts Hu Lamb Growth

Ciltacabtagene Autoleucel vs. Real-World Therapy in Myeloma

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.